...
首页> 外文期刊>Emerging Infectious Diseases >Quinolone and Macrolide Resistance in Campylobacter jejuni and C. coli: Resistance Mechanisms and Trends in Human Isolates
【24h】

Quinolone and Macrolide Resistance in Campylobacter jejuni and C. coli: Resistance Mechanisms and Trends in Human Isolates

机译:空肠弯曲菌和大肠杆菌中的喹诺酮和大环内酯类抗药性:人类分离物的抗性机制和趋势

获取原文

摘要

The incidence of human Campylobacter jejuni and C. coli infections has increased markedly in many parts of the world in the last decade as has the number of quinoloneresistant and, to a lesser extent, macrolide-resistant Campylobacter strains causing infections. We review macrolide and quinolone resistance in Campylobacter and track resistance trends in human clinical isolates in relation to use of these agents in food animals. Susceptibility data suggest that erythromycin and other macrolides should remain the drugs of choice in most regions, with systematic surveillance and control measures maintained, but fluoroquinolones may now be of limited use in the empiric treatment of Campylobacter infections in many regions.
机译:在过去的十年中,空肠弯曲杆菌和大肠杆菌感染的发生率在世界许多地区显着增加,其中喹诺酮耐药性和引起感染的对大环内酯类耐药的弯曲杆菌菌株的数量有所增加。我们审查弯曲杆菌对大环内酯和喹诺酮类药物的耐药性,并追踪与这些药物在食用动物中的使用有关的人类临床分离株的耐药性趋势。药敏性数据表明,在大多数地区,应保持系统监视和控制措施,而在大多数地区仍应选择红霉素和其他大环内酯类药物,但氟喹诺酮类药物目前在许多地区的弯曲杆菌感染的经验性治疗中用途有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号